Track your brain health with blood tests and digital monitoring over two years

Back to Mild Cognitive Impairment (MCI) trials

Recruiting

What is this trial?

This is a two-year research study that aims to predict who will develop early signs of memory and thinking problems due to Alzheimer's disease. The study combines information from your genes, blood tests, digital devices (like smartwatches and smartphone apps), and cognitive tests to identify your risk level. It focuses on people age 55 and older who carry a specific genetic marker linked to Alzheimer's risk and who currently have normal or very mild thinking abilities.

Alzheimer's disease develops slowly over many years, often silently in the brain before a person notices memory problems. Recently, scientists discovered that certain blood markers can detect early Alzheimer's changes years before symptoms appear. This study aims to develop better tools that combine genetic risk, blood tests, and digital monitoring to identify people at highest risk—so they might benefit from earlier interventions or closer monitoring.

Do you qualify?

You likely qualify if…

you are age 55 or older
you carry at least one copy of the APOE ε4 gene variant (a genetic risk factor for Alzheimer's)
you already have genetic test results available (whole-genome sequencing or genetic array data) that you can share with the study
you currently have normal memory and thinking abilities, or only very mild thinking difficulties
you are willing to wear digital devices like smartwatches or use smartphone apps for cognitive testing throughout the study
you are able to give informed consent and complete study visits and blood draws

You likely don't qualify if…

you have been diagnosed with dementia
you have a history of major neurological conditions like Parkinson's disease, stroke with lasting effects, or frequent seizures
you have uncontrolled major depression or another serious psychiatric illness that would interfere with participating
you already show signs of mild cognitive impairment due to Alzheimer's disease based on blood biomarker testing
you are unable or unwilling to use digital monitoring devices or share your genetic and medical data

What participation looks like

Over two years, you would attend clinic visits to complete memory and thinking tests, provide blood samples, and share existing genetic test results with the research team. You would be asked to wear a digital device like a smartwatch (Oura Ring) and use smartphone apps to track daily activities, sleep, and cognition. Some participants will also take a speech-based assessment. The study team will use all this information—your genes, blood markers, daily activity patterns, and cognitive test results—to develop and refine a prediction tool for early memory changes.

Predicting early memory changes using blood tests and wearables

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)